

# **Vaginitis Therapeutics Market Forecasts to 2034 – Global Analysis By Disease Type (Atrophic Vaginitis, Bacterial vaginosis (BV), Trichomoniasis and Other Disease Types), By Treatment (Prescription Drugs, Natural and Herbal Remedies, Over-the-counter (OTC) Drugs and Probiotics and Vaginal Suppositories), Distribution Channel and By Geography**

<https://marketpublishers.com/r/V715BFDFCA3FEN.html>

Date: May 2026

Pages: 200

Price: US\$ 4,150.00 (Single User License)

ID: V715BFDFCA3FEN

## **Abstracts**

According to Statistics MRC, the Global Vaginitis Therapeutics Market is accounted for \$4.7 billion in 2026 and is expected to reach \$10.3 billion by 2034 growing at a CAGR of 10.3% during the forecast period. Vaginitis therapeutics encompasses medical interventions aimed at treating inflammation or infection of the vagina, a condition known as vaginitis. Common causes include bacterial, fungal or viral infections and treatment often involves antimicrobial medications, antifungals, or antivirals. Additionally, managing underlying factors like hormonal imbalances or irritants is crucial. Personalized care may include topical or oral medications, lifestyle modifications and addressing contributing factors to alleviate symptoms and restore vaginal health.

According to the CDC, about 30% of women in the U.S. experience vaginitis at frequent intervals.

### **Market Dynamics:**

#### **Driver:**

Heightened awareness about women's health and vaginal infections

Increased awareness about women's health and vaginal infections acts as a pivotal driver in vaginitis therapeutics. It fosters a proactive approach to healthcare, encouraging women to recognize symptoms early, seek prompt medical attention and adopt preventive measures. This awareness promotes education initiatives, facilitates open discussions and reduces stigma surrounding vaginal health issues. Consequently, it leads to improved healthcare-seeking behaviour, earlier diagnosis, and timely intervention, driving the demand for effective therapies.

**Restraint:**

Limited healthcare access

Limited healthcare access serves as a significant restraint in vaginitis therapeutics. It encompasses various barriers such as inadequate healthcare infrastructure, especially in rural or underserved areas, leading to reduced availability of medical facilities and specialists. Additionally, financial constraints and disparities in access prevent some individuals from seeking timely diagnosis and treatment. This limitation exacerbates underdiagnosis, delays in care and impedes the dissemination of crucial information and treatments, thereby restricting effective management of vaginitis among affected populations.

**Opportunity:**

Increasing adoption of telemedicine facilitates

The growing adoption of telehealth presents an opportunity in the vaginitis therapeutics market due to its integration with remote diagnostics and treatments. As telehealth expands, there is a need for accurate radiation monitoring tools. These devices become crucial in ensuring patient safety by remotely assessing radiation exposure during telemedicine sessions involving imaging or radiation therapies. Innovations in radiation detection technologies catering to telehealth settings offer a chance for companies to develop portable, user-friendly, and precise detectors, thereby tapping into this evolving market demand.

**Threat:**

Clinical trial challenges

Limited education and resources hinder the adoption of proper radiation safety

measures and the understanding of detection technologies. This can lead to increased risks of overexposure to radiation for both patients and healthcare workers, impacting their health. Additionally, the absence of stringent regulations and insufficient infrastructure investment further exacerbate this issue, potentially resulting in higher incidences of radiation-related health complications and impeding the market's growth due to a lack of demand for advanced detection solutions.

### **Covid-19 Impact:**

The COVID-19 pandemic has influenced the market by altering healthcare priorities. With healthcare systems focusing on combating the pandemic, attention and resources shifted away from non-emergency conditions like vaginitis. Disruptions in healthcare access, supply chains, and patient behaviour also affected diagnosis and treatment-seeking patterns, impacting the market dynamics for vaginitis therapeutics during the pandemic period.

The prescription drugs segment is expected to be the largest during the forecast period

The prescription drugs segment is anticipated to be the largest during the forecast period owing to the growing prevalence of chronic diseases and the increasing need for specialized medical interventions. As healthcare awareness rises, there is a surge in demand for prescription medications to address specific health conditions. Additionally, regulatory approvals and advancements in pharmaceutical research contribute to the prominence of this segment.

The online pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacies segment is projected to achieve a high growth rate during the forecast period due to increasing digitalization, convenience and accessibility of healthcare services. As consumers prioritise the ease of purchasing medications from the comfort of their homes, online pharmacies offer a compelling solution. The adoption of telemedicine, coupled with advancements in e-commerce, fosters the rapid growth of this segment.

### **Region with largest share:**

North America is positioned to dominate the market, primarily attributed to advanced healthcare infrastructure, high awareness levels, and a robust emphasis on women's

health. The region's leading market share is further propelled by well-established research and development activities, a strong regulatory framework, and a proactive approach toward adopting innovative therapies. Increasing incidences of vaginitis, coupled with a growing aging population, contribute to the demand for effective therapeutics, reinforcing North America's pivotal role in capturing the largest market share in the vaginitis therapeutics market.

### **Region with highest CAGR:**

The Asia-Pacific region is experiencing significant growth in the market due to rising awareness, increasing healthcare infrastructure and a growing emphasis on women's health. Factors such as improved access to healthcare services, changing lifestyles, and a rising incidence of vaginitis contribute to the region's poised expansion. Additionally, advancements in medical research and technology, coupled with supportive government initiatives, create a favourable environment for the development and adoption of innovative vaginitis therapeutics, driving substantial market growth in the Asia-Pacific region.

### **Key players in the market**

Some of the key players in Vaginitis Therapeutics Market include Astellas Pharma, AstraZeneca PLC, Bausch Health Companies Inc, Bayer AG, Biocon Limited, Cipla Inc., Ferring Pharmaceuticals, GlaxoSmithKline plc, Hologic, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Perrigo Company plc, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. and TherapeuticsMD, Inc.

### **Key Developments:**

In January 2023, Astellas Pharma acquired Shionogi & Co.'s global women's health franchise, which includes the Vagifem vaginal ring for the treatment of recurrent vulvovaginal candidiasis (RVVC).

In May 2022, Bayer acquired FemTec, including Vagisan, a vaginal moisturizer. Additionally, Seres Therapeutics introduced SER-109, a microbiome-based therapy for recurrent vulvovaginal candidiasis (RVVC).

In April 2022, Pfizer introduced Daivobet, a topical cream combining steroids and vitamin D, designed to treat vulvovaginal candidiasis (VVC). Daivobet stands as the

sole FDA-approved topical cream with this combination for VVC treatment.

#### Disease Types Covered:

Atrophic Vaginitis

Bacterial vaginosis (BV)

Trichomoniasis

Vulvovaginal Candidiasis (VVC)

Other Disease Types

#### Treatments Covered:

Prescription Drugs

Natural and Herbal Remedies

Over-the-counter (OTC) Drugs

Probiotics and Vaginal Suppositories

#### Distribution Channels Covered:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Other Distribution Channels

#### Regions Covered:

## North America

US

Canada

Mexico

## Europe

Germany

UK

Italy

France

Spain

Rest of Europe

## Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

## South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

### **What our report offers:**

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

### **Free Customization Offerings:**

All the customers of this report will be entitled to receive one of the following free customization options:

## Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

## Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

## Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

## Contents

### **1 EXECUTIVE SUMMARY**

### **2 PREFACE**

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
  - 2.4.1 Data Mining
  - 2.4.2 Data Analysis
  - 2.4.3 Data Validation
  - 2.4.4 Research Approach
- 2.5 Research Sources
  - 2.5.1 Primary Research Sources
  - 2.5.2 Secondary Research Sources
  - 2.5.3 Assumptions

### **3 MARKET TREND ANALYSIS**

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Emerging Markets
- 3.7 Impact of Covid-19

### **4 PORTERS FIVE FORCE ANALYSIS**

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

### **5 GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISEASE TYPE**

- 5.1 Introduction
- 5.2 Atrophic Vaginitis
- 5.3 Bacterial vaginosis (BV)
- 5.4 Trichomoniasis
- 5.5 Vulvovaginal Candidiasis (VVC)
- 5.6 Other Disease Types

## **6 GLOBAL VAGINITIS THERAPEUTICS MARKET, BY TREATMENT**

- 6.1 Introduction
- 6.2 Prescription Drugs
- 6.3 Natural and Herbal Remedies
- 6.4 Over-the-counter (OTC) Drugs
- 6.5 Probiotics and Vaginal Suppositories

## **7 GLOBAL VAGINITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

- 7.1 Introduction
- 7.2 Hospital Pharmacies
- 7.3 Retail Pharmacies
- 7.4 Online Pharmacies
- 7.5 Other Distribution Channels

## **8 GLOBAL VAGINITIS THERAPEUTICS MARKET, BY GEOGRAPHY**

- 8.1 Introduction
- 8.2 North America
  - 8.2.1 US
  - 8.2.2 Canada
  - 8.2.3 Mexico
- 8.3 Europe
  - 8.3.1 Germany
  - 8.3.2 UK
  - 8.3.3 Italy
  - 8.3.4 France
  - 8.3.5 Spain
  - 8.3.6 Rest of Europe
- 8.4 Asia Pacific
  - 8.4.1 Japan

- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
  - 8.5.1 Argentina
  - 8.5.2 Brazil
  - 8.5.3 Chile
  - 8.5.4 Rest of South America
- 8.6 Middle East & Africa
  - 8.6.1 Saudi Arabia
  - 8.6.2 UAE
  - 8.6.3 Qatar
  - 8.6.4 South Africa
  - 8.6.5 Rest of Middle East & Africa

## **9 KEY DEVELOPMENTS**

- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies

## **10 COMPANY PROFILING**

- 10.1 Astellas Pharma
- 10.2 AstraZeneca PLC
- 10.3 Bausch Health Companies Inc
- 10.4 Bayer AG
- 10.5 Biocon Limited
- 10.6 Cipla Inc.
- 10.7 Ferring Pharmaceuticals
- 10.8 GlaxoSmithKline plc
- 10.9 Hologic, Inc.
- 10.10 Johnson & Johnson
- 10.11 Lupin Pharmaceuticals, Inc.

- 10.12 Merck & Co., Inc.
- 10.13 Mylan N.V.
- 10.14 Novartis AG
- 10.15 Perrigo Company plc
- 10.16 Pfizer Inc.
- 10.17 Sanofi
- 10.18 Sun Pharmaceutical Industries Ltd.
- 10.19 Teva Pharmaceutical Industries Ltd.
- 10.20 TherapeuticsMD, Inc.

## List Of Tables

### LIST OF TABLES

Table 1 Global Vaginitis Therapeutics Market Outlook, By Region (2023-2034) (\$MN)

Table 2 Global Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 3 Global Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 4 Global Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 5 Global Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 6 Global Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 7 Global Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) (\$MN)

Table 8 Global Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 9 Global Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 10 Global Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 11 Global Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 12 Global Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) (\$MN)

Table 13 Global Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 14 Global Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 15 Global Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 16 Global Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 17 Global Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 18 North America Vaginitis Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 19 North America Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 20 North America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 21 North America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 22 North America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 23 North America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 24 North America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) (\$MN)

Table 25 North America Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 26 North America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 27 North America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 28 North America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 29 North America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) (\$MN)

Table 30 North America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 31 North America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 32 North America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 33 North America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 34 North America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 35 Europe Vaginitis Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 36 Europe Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 37 Europe Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 38 Europe Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 39 Europe Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 40 Europe Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 41 Europe Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) (\$MN)

Table 42 Europe Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 43 Europe Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 44 Europe Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 45 Europe Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 46 Europe Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) (\$MN)

Table 47 Europe Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 48 Europe Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 49 Europe Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 50 Europe Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 51 Europe Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 52 Asia Pacific Vaginitis Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 53 Asia Pacific Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 54 Asia Pacific Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 55 Asia Pacific Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 56 Asia Pacific Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 57 Asia Pacific Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 58 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Disease Types

(2023-2034) (\$MN)

Table 59 Asia Pacific Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 60 Asia Pacific Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 61 Asia Pacific Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 62 Asia Pacific Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 63 Asia Pacific Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) (\$MN)

Table 64 Asia Pacific Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 65 Asia Pacific Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 66 Asia Pacific Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 67 Asia Pacific Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 68 Asia Pacific Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 69 South America Vaginitis Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 70 South America Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 71 South America Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 72 South America Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 73 South America Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 74 South America Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 75 South America Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) (\$MN)

Table 76 South America Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 77 South America Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 78 South America Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 79 South America Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 80 South America Vaginitis Therapeutics Market Outlook, By Probiotics and Vaginal Suppositories (2023-2034) (\$MN)

Table 81 South America Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 82 South America Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 83 South America Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 84 South America Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 85 South America Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

Table 86 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Country (2023-2034) (\$MN)

Table 87 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Disease Type (2023-2034) (\$MN)

Table 88 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Atrophic Vaginitis (2023-2034) (\$MN)

Table 89 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Bacterial vaginosis (BV) (2023-2034) (\$MN)

Table 90 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Trichomoniasis (2023-2034) (\$MN)

Table 91 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Vulvovaginal Candidiasis (VVC) (2023-2034) (\$MN)

Table 92 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Disease Types (2023-2034) (\$MN)

Table 93 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Treatment (2023-2034) (\$MN)

Table 94 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Prescription Drugs (2023-2034) (\$MN)

Table 95 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Natural and Herbal Remedies (2023-2034) (\$MN)

Table 96 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Over-the-counter (OTC) Drugs (2023-2034) (\$MN)

Table 97 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Probiotics and

Vaginal Suppositories (2023-2034) (\$MN)

Table 98 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Distribution Channel (2023-2034) (\$MN)

Table 99 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Hospital Pharmacies (2023-2034) (\$MN)

Table 100 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Retail Pharmacies (2023-2034) (\$MN)

Table 101 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Online Pharmacies (2023-2034) (\$MN)

Table 102 Middle East & Africa Vaginitis Therapeutics Market Outlook, By Other Distribution Channels (2023-2034) (\$MN)

## I would like to order

Product name: Vaginitis Therapeutics Market Forecasts to 2034 – Global Analysis By Disease Type (Atrophic Vaginitis, Bacterial vaginosis (BV), Trichomoniasis and Other Disease Types), By Treatment (Prescription Drugs, Natural and Herbal Remedies, Over-the-counter (OTC) Drugs and Probiotics and Vaginal Suppositories), Distribution Channel and By Geography

Product link: <https://marketpublishers.com/r/V715BFDFCA3FEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V715BFDFCA3FEN.html>